OTCPK:CSWYY (China)
Â
ADR
$
18.53
0 (0%)
11:09 PM EST
Business Description
China Shineway Pharmaceutical Group Ltd
NAICS : 325412
ISIN : US16947J1007
Share Class Description:
CSWYY: ADRCompare
Compare
Traded in other countries / regions
02877.Hong KongC1S.GermanyCSWYY.USA IPO Date
2008-10-13Description
China Shineway Pharmaceutical Group Ltd is an investment holding company in the People's Republic of China. It is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, and others of which injection generates maximum revenue to the company.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 17.76 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | 0.24 | |||||
| Interest Coverage | 174.81 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 4.05 | |||||
| Beneish M-Score | -2.42 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 16.3 | |||||
| 3-Year EBITDA Growth Rate | 28.4 | |||||
| 3-Year EPS without NRI Growth Rate | 29.4 | |||||
| 3-Year FCF Growth Rate | 8.4 | |||||
| 3-Year Book Growth Rate | 7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 11.22 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 8.38 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 0.05 | |||||
| 6-1 Month Momentum % | -23.81 | |||||
| 12-1 Month Momentum % | -1.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.48 | |||||
| Quick Ratio | 3.14 | |||||
| Cash Ratio | 2.56 | |||||
| Days Inventory | 295.81 | |||||
| Days Sales Outstanding | 68.39 | |||||
| Days Payable | 155.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 8.03 | |||||
| Dividend Payout Ratio | 0.37 | |||||
| 3-Year Dividend Growth Rate | 19.1 | |||||
| Forward Dividend Yield % | 8.03 | |||||
| 5-Year Yield-on-Cost % | 12.58 | |||||
| 3-Year Average Share Buyback Ratio | 3 | |||||
| Shareholder Yield % | 3.66 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.21 | |||||
| Operating Margin % | 22.52 | |||||
| Net Margin % | 26.24 | |||||
| FCF Margin % | 25.51 | |||||
| ROE % | 15.72 | |||||
| ROA % | 11.64 | |||||
| ROIC % | 32.75 | |||||
| 3-Year ROIIC % | 201.81 | |||||
| ROC (Joel Greenblatt) % | 117.3 | |||||
| ROCE % | 20.04 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 5.83 | |||||
| Forward PE Ratio | 4.19 | |||||
| PE Ratio without NRI | 5.82 | |||||
| Shiller PE Ratio | 9.93 | |||||
| Price-to-Owner-Earnings | 6.65 | |||||
| PEG Ratio | 0.49 | |||||
| PS Ratio | 1.53 | |||||
| PB Ratio | 0.88 | |||||
| Price-to-Tangible-Book | 0.91 | |||||
| Price-to-Free-Cash-Flow | 5.99 | |||||
| Price-to-Operating-Cash-Flow | 5.46 | |||||
| EV-to-EBIT | 0.35 | |||||
| EV-to-EBITDA | 0.35 | |||||
| EV-to-Revenue | 0.12 | |||||
| EV-to-FCF | 0.47 | |||||
| Price-to-Projected-FCF | 0.44 | |||||
| Price-to-Median-PS-Value | 0.59 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.55 | |||||
| Price-to-Graham-Number | 0.48 | |||||
| Price-to-Net-Current-Asset-Value | 1.1 | |||||
| Price-to-Net-Cash | 1.76 | |||||
| Earnings Yield (Greenblatt) % | 285.71 | |||||
| FCF Yield % | 16.7 | |||||
| Forward Rate of Return (Yacktman) % | 21.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CSWYY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
China Shineway Pharmaceutical Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 584.244 | ||
| EPS (TTM) ($) | 4.053 | ||
| Beta | 0.82 | ||
| Volatility % | 41.3 | ||
| 14-Day RSI | 0.05 | ||
| 14-Day ATR ($) | 0.00726 | ||
| 20-Day SMA ($) | 18.53 | ||
| 12-1 Month Momentum % | -1.44 | ||
| 52-Week Range ($) | 18.53 - 27.85 | ||
| Shares Outstanding (Mil) | 37.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
China Shineway Pharmaceutical Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
China Shineway Pharmaceutical Group Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
China Shineway Pharmaceutical Group Ltd Frequently Asked Questions
What is China Shineway Pharmaceutical Group Ltd(CSWYY)'s stock price today?
The current price of CSWYY is $18.53. The 52 week high of CSWYY is $27.85 and 52 week low is $18.53.
When is next earnings date of China Shineway Pharmaceutical Group Ltd(CSWYY)?
The next earnings date of China Shineway Pharmaceutical Group Ltd(CSWYY) is .
Does China Shineway Pharmaceutical Group Ltd(CSWYY) pay dividends? If so, how much?
The Dividend Yield %  of China Shineway Pharmaceutical Group Ltd(CSWYY) is 8.03% (As of Today), Highest Dividend Payout Ratio of China Shineway Pharmaceutical Group Ltd(CSWYY) was 0.8. The lowest was 0.3. And the median was 0.35. The  Forward Dividend Yield % of China Shineway Pharmaceutical Group Ltd(CSWYY) is 8.03%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers